Clinical Trials Sponsored by Institut Pasteur

Total 75049 results

Sanofi Pasteur, a Sanofi Company

Completed

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

Pertussis | Whooping Cough | Tetanus | Diphtheria

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America

Dengue | Dengue Hemorrhagic Fever

Brazil
Aeras
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Tuberculosis

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea

Influenza

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Diarrhea | Clostridium Difficile Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infection

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older

Pertussis | Tetanus | Diphtheria | Poliomyelitis

France, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults

Healthy

France, Germany
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

Hepatitis B

Italy
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b Infection

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Influenza

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Assess the Safety of Adacel® Vaccine

Pertussis | Tetanus | Diphtheria

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Study of IMOJEV® in Thailand

Japanese Encephalitis

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td

Tetanus | Diphtheria

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

Meningitis | Meningococcal Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Trial to Collect Safety Data and Sera for Immunogenicity Testing

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Dose Comparison Study of Menactra® in US Children

Meningitis | Meningococcal Infection | Neisseria Meningitidis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

Meningitis | Meningococcemia

United States
Sanofi Pasteur, a Sanofi Company

Completed

Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Colombia, Costa Rica
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)

Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents

Hepatitis A | Hepatitis A Virus

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age

Measles | Pertussis | Tetanus | Diphtheria | Polio

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults

Influenza

United States, Puerto Rico, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan

Poliomyelitis | Polio

Japan
Sanofi Pasteur, a Sanofi Company

Completed

36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Meningitis | Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine

Rabies | Rabies Virus

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects

Bacterial Infections | Typhoid Fever | Salmonella Infections

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Hepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type b

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose

Pertussis | Tetanus | Diphtheria

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents

Pertussis | Tetanus | Diphtheria

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

Meningitis | Meningococcemia

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

Meningitis | Neisseria Meningitidis | Meningococcemia

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose

Hepatitis A

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly

Poliomyelitis

Philippines
Sanofi Pasteur, a Sanofi Company

Terminated

Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

Smallpox

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV

Poliomyelitis | Polio

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation

Influenza | Orthomyxoviridae Infections

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

Switzerland, United Kingdom

3

Subscribe